15 results on '"Schäfer, Michael"'
Search Results
2. The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats
- Author
-
Balogh, Mihály, Zádori, Zoltán S., Lázár, Bernadette, Karádi, Dávid, László, Szilvia, Mousa, Shaaban A., Hosztafi, Sándor, Zádor, Ferenc, Riba, Pál, Schäfer, Michael, Fürst, Susanna, and Al-Khrasani, Mahmoud
- Published
- 2018
- Full Text
- View/download PDF
3. Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements.
- Author
-
Müller-Schwefe, Gerhard, Ahlbeck, Karsten, Aldington, Dominic, Alon, Eli, Coaccioli, Stefano, Coluzzi, Flaminia, Huygen, Frank, Jaksch, Wolfgang, Kalso, Eija, Kocot-Kępska, Magdalena, Kress, Hans-Georg, Mangas, Ana Cristina, Ferri, Cesar Margarit, Morlion, Bart, Nicolaou, Andrew, Hernández, Concepción Pérez, Pergolizzi, Joseph, Schäfer, Michael, and Sichère, Patrick
- Subjects
CANCER pain treatment ,CANCER patients ,ANALGESICS ,PSYCHOTHERAPY research ,EXERCISE therapy ,ELECTRIC stimulation research - Abstract
Twenty years ago, the main barriers to successful cancer pain management were poor assessment by physicians, and patients' reluctance to report pain and take opioids. Those barriers are almost exactly the same today. Cancer pain remains under-treated; in Europe, almost three-quarters of cancer patients experience pain, and almost a quarter of those with moderate to severe pain do not receive any analgesic medication. Yet it has been suggested that pain management could be improved simply by ensuring that every consultation includes the patient's rating of pain, that the physician pays attention to this rating, and a plan is agreed to increase analgesia when it is inadequate. After outlining current concepts of carcinogenesis in some detail, this paper describes different methods of classifying and diagnosing cancer pain and the extent of current under-treatment. Key points are made regarding cancer pain management. Firstly, the pain may be caused by multiple different mechanisms and therapy should reflect those underlying mechanisms - rather than being simply based on pain intensity as recommended by the WHO three-step ladder. Secondly, a multidisciplinary approach is required which combines both pharmacological and non-pharmacological treatment, such as psychotherapy, exercise therapy and electrostimulation. The choice of analgesic agent and its route of administration are considered, along with various interventional procedures and the requirements of palliative care. Special attention is paid to the treatment of breakthrough pain (particularly with fast-acting fentanyl formulations, which have pharmacokinetic profiles that closely match those of breakthrough pain episodes) and chemotherapy-induced neuropathic pain, which affects around one third of patients who receive chemotherapy. Finally, the point is made that medical education should place a greater emphasis on pain therapy, both at undergraduate and postgraduate level. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Reduced Number, G Protein Coupling, and Antinociceptive Efficacy of Spinal Mu-Opioid Receptors in Diabetic Rats Are Reversed by Nerve Growth Factor.
- Author
-
Shaqura, Mohammed, Khalefa, Baled I., Shakibaei, Mehdi, Winkler, Jens, Al-Khrasani, Mahmoud, Fürst, Susanna, Mousa, Shaaban A., and Schäfer, Michael
- Abstract
Abstract: This study investigated putative mechanisms of impaired spinal opioid antinociception such as a downregulation of mu-opioid receptor (MOR) number, coupling, and efficacy in rats with advanced (12 weeks) streptozotocin (STZ)-induced diabetes. Intravenous injection of STZ (45 mg/kg) in Wistar rats led to selective degeneration of insulin-producing pancreatic ß-cells, elevated blood glucose, and mechanical hyperalgesia. In these animals, dose-dependent and naloxone-reversible intrathecal fentanyl antinociception was significantly impaired and associated with a loss in MOR immunoreactivity of calcitonin gene-related peptide–immunoreactive (CGRP-IR) sensory nerve terminals, membrane-bound MOR binding sites, and MOR-stimulated G protein coupling within the dorsal horn of the spinal cord. Intrathecal delivery of nerve growth factor (NGF) in diabetic animals normalized spinal MOR number and G protein coupling and rescued spinal fentanyl-induced antinociception. These findings identify for the first time a loss in functional MOR on central terminals of sensory neurons as a contributing factor for the impaired spinal opioid responsiveness during advanced STZ-induced diabetes that can be reversed by NGF. Moreover, they support growing evidence of a distinct regulation of opioid responsiveness during various painful states of disease (eg, arthritis, cancer, neuropathy) and may give novel therapeutic incentives. Perspective: In diabetic neuropathy a loss in sensory neuron mu-opioid receptor number and coupling contributes to impaired spinal opioid antinociception that can be reversed by NGF. These findings support growing evidence of a distinct regulation of opioid responsiveness during various painful diseases and may give novel therapeutic incentives. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
5. Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue.
- Author
-
Binder, Waltraud, Mousa, Shaaban A., Sitte, Nicolle, Kaiser, Myriam, Stein, Christoph, and Schäfer, Michael
- Subjects
INFLAMMATION ,NORADRENALINE ,PAIN ,SYMPATHETIC nervous system ,OPIOIDS ,ANALGESIA - Abstract
Stress induces analgesia by mechanisms within and outside the brain. Here we show that the sympathetic nervous system is an essential trigger of intrinsic opioid analgesia within peripheral injured tissue. Noradrenaline, injected directly into inflamed hind paws of male Wistar rats, produced dose-dependent antinociception, reversible by α
1 -, α2 - and β2 -antagonists. α1 -, α2 - and β2 -adrenergic receptors were demonstrated on β-endorphin-containing immune cells and noradrenaline induced adrenergic receptor-specific release of β-endorphin from immune cell suspensions. This antinociceptive effect of noradrenaline was reversed by µ- and δ-opioid antagonists as well as by anti-β-endorphin. Stress-induced peripheral analgesia was abolished by chemical sympathectomy and by adrenergic antagonists. These findings indicate that sympathetic neuron-derived noradrenaline stimulates adrenergic receptors on inflammatory cells to release β-endorphin, which induces analgesia via activation of peripheral opioid receptors. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
6. Selectins and integrins but not platelet-endothelial cell adhesion molecule-1 regulate opioid inhibition of inflammatory pain.
- Author
-
Machelska, Halina, Brack, Alexander, Mousa, Shaaban A., Schopohl, Julia K., Rittner, Heike L., Schäfer, Michael, and Stein, Christoph
- Subjects
INFLAMMATION ,SELECTINS ,INTEGRINS ,BLOOD platelets ,CELL adhesion molecules ,OPIOIDS ,PAIN - Abstract
1: Control of inflammatory pain can result from activation of opioid receptors on peripheral sensory nerves by opioid peptides secreted from leukocytes in response to stress (e.g. experimental swim stress or surgery). The extravasation of immunocytes to injured tissues involves rolling, adhesion and transmigration through the vessel wall, orchestrated by various adhesion molecules. 2: Here we evaluate the relative contribution of selectins, integrins a
4 and ß2 , and platelet-endothelial cell adhesion molecule-1 (PECAM-1) to the opioid-mediated inhibition of inflammatory pain. 3: We use flow cytometry, double immunofluorescence and nociceptive (paw pressure) testing in rats with unilateral hind paw inflammation induced by complete Freund's adjuvant. 4: In inflamed tissue, 43-58% of hematopoietic cells (CD45+ ) expressed opioid peptides. L-selectin and ß2 were coexpressed by 7 and 98% of opioid-containing leukocytes, respectively. Alpha4 integrin was expressed in low levels by the majority of leukocytes. Opioid-containing cells, vascular P- and E-selectin and PECAM-1 were simultaneously upregulated. 5: Swim stress produced potent opioid-mediated antinociception in inflamed tissue, unaffected by blockade of PECAM-1. However, blockade of L- and P-selectins by fucoidin, or of a4 and ß2 by monoclonal antibodies completely abolished peripheral stress-induced antinociception. This coincided with a 40% decrease in the migration of opioid-containing leukocytes to inflamed tissue. 6: These findings establish selectins and integrins a4 and ß2 , but not PECAM-1, as important molecules involved in stress-induced opioid-mediated antinociception in inflammation. They point to a cautious use of anti-inflammatory treatments applying anti-selectin, anti-a4 and anti-ß2 strategies because they may impair intrinsic pain inhibition.British Journal of Pharmacology (2004) 142, 772-780. doi:10.1038/sj.bjp.0705837 [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
7. Attacking pain at its source: new perspectives on opioids.
- Author
-
Stein, Christoph, Schäfer, Michael, and Machelska, Halina
- Subjects
- *
PAIN management , *OPIOIDS , *CENTRAL nervous system - Abstract
The treatment of severe pain with opioids has thus far been limited by their unwanted central side effects. Recent research promises new approaches, including opioid analgesics acting outside the central nervous system, targeting of opioid peptide-containing immune cells to peripheral damaged tissue, and gene transfer to enhance opioid production at sites of injury. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
8. Pharmacotherapy in Pain Patients with Substance Abuse.
- Author
-
Schäfer, Michael, Denke, Claudia, Krampe, Henning, and Spies, Claudia
- Subjects
- *
CHRONIC pain , *DRUG addiction , *DRUGS , *PAIN , *SUBSTANCE abuse , *ACUTE diseases , *DISEASE complications - Abstract
Definitions and difficulties relating to managing acute and chronic pain in patients with current or past substance abuse disorders are discussed. Problems with too rapid discontinuation of drugs are described. An interdisciplinary approach involving pain specialists, substance abuse clinicians and mental health professional is advocated. This report is adapted from paineurope 2014; Issue 3, ©Haymarket Medical Publications Ltd, and is presented with permission. paineurope is provided as a service to pain management by Mundipharma International, LTD and is distributed free of charge to healthcare professionals in Europe. Archival issues can be accessed via the website: at which European health professionals can register online to receive copies of the quarterly publication. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Protein kinase C-mediated mu-opioid receptor phosphorylation and desensitization in rats, and its prevention during early diabetes.
- Author
-
Mousa, Shaaban A., Shaqura, Mohammed, Winkler, Jens, Khalefa, Baled I., Al-Madol, Mohammed A., Shakibaei, Mehdi, Schulz, Stefan, and Schäfer, Michael
- Subjects
- *
TREATMENT of diabetic neuropathies , *OPIOIDS , *ANALGESIA , *SENSORY neurons , *STREPTOZOTOCIN , *ANALGESICS , *ANIMAL experimentation , *CELL receptors , *COMPARATIVE studies , *DIABETES , *DIABETIC neuropathies , *RESEARCH methodology , *MEDICAL cooperation , *NARCOTICS , *PHOSPHORYLATION , *RATS , *RESEARCH , *SENSORY receptors , *TRANSFERASES , *EVALUATION research , *PHARMACODYNAMICS - Abstract
Painful diabetic neuropathy is associated with impaired opioid analgesia; however, the precise mechanism in sensory neurons remains unclear. This study aimed to identify putative mechanisms involved in modified opioid responsiveness during early streptozotocin-induced diabetes in rats. In this study, we demonstrate that in diabetic animals, impaired peripheral opioid analgesia is associated with a reduction in functional mu-opioid receptor (MOR) G protein coupling. Mu-opioid receptor immunoreactive neurons colocalized with activated forms of protein kinase C (PKC) and with the receptor for advanced glycation end products (RAGE) during streptozotocin-induced diabetes. Moreover, MOR phosphorylation at Thr370 in sensory neurons of diabetic rats, and thus desensitization, was due to RAGE-dependent PKC activation. Importantly, blocking PKC activation using PKC selective inhibitor, silencing RAGE with intrathecal RAGE siRNA, or inhibiting advanced glycation end product (AGE) formation prevented sensory neuron MOR phosphorylation and, consequently, restored MOR G protein coupling and analgesic efficacy. Thus, our findings give the first in vivo evidence of a RAGE-dependent PKC-mediated heterologous MOR phosphorylation and desensitization in sensory neurons under pathological conditions such as diabetic neuropathy. This may unravel putative mechanisms and suggest possible prevention strategies of impaired opioid responsiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. New insights into mechanisms of opioid inhibitory effects on capsaicin-induced TRPV1 activity during painful diabetic neuropathy.
- Author
-
Shaqura, Mohammed, Khalefa, Baled. I., Shakibaei, Mehdi, Zöllner, Christian, Al-Khrasani, Mahmoud, Fürst, Susanna, Schäfer, Michael, and Mousa, Shaaban A.
- Subjects
- *
OPIOIDS , *TREATMENT of diabetic neuropathies , *TRPV cation channels , *CHEMICAL inhibitors , *DRUG side effects , *SENSORY neurons - Abstract
Painful diabetic neuropathy is a disease of the peripheral sensory neuron with impaired opioid responsiveness. Since μ-opioid receptor (MOR) activation can inhibit the transient receptor potential vanilloid 1 (TRPV1) activity in peripherally sensory neurons, this study investigated the mechanisms of impaired opioid inhibitory effects on capsaicin-induced TRPV1 activity in painful diabetic neuropathy. Intravenous injection of streptozotocin (STZ, 45 mg/kg) in Wistar rats led to a degeneration of insulin producing pancreatic β-cells, elevated blood glucose, and mechanical hypersensitivity (allodynia). In these animals, local morphine's inhibitory effects on capsaicin-induced nocifensive behavior as well as on capsaicin-induced TRPV1 current in dorsal root ganglion cells were significantly impaired. These changes were associated with a loss in MOR but not TRPV1 in peripheral sensory neurons. Intrathecal delivery of nerve growth factor in diabetic animals normalized sensory neuron MOR and subsequently rescued morphine's inhibitory effects on capsaicin-induced TRPV1 activity in vivo and in vitro. These findings identify a loss in functional MOR on sensory neurons as a contributing factor for the impaired opioid inhibitory effects on capsaicin-induced TRPV1 activity during advanced STZ-induced diabetes. Moreover, they support growing evidence of a distinct regulation of opioid responsiveness during various painful states of disease (e.g. arthritis, cancer, neuropathy) and may give novel therapeutic incentives. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner
- Author
-
Spahn, Viola, Fischer, Oliver, Endres-Becker, Jeannette, Schäfer, Michael, Stein, Christoph, and Zöllner, Christian
- Subjects
- *
OPIOIDS , *TRP channels , *CYCLIC-AMP-dependent protein kinase , *HYPERALGESIA , *CYCLIC adenylic acid , *ADENYLATE cyclase - Abstract
Abstract: Hyperalgesia is a cardinal symptom of opioid withdrawal. The transient receptor potential vanilloid 1 (TRPV1) is a ligand-gated ion channel expressed on sensory neurons responding to noxious heat, protons, and chemical stimuli such as capsaicin. TRPV1 can be inhibited via μ-opioid receptor (MOR)-mediated reduced activity of adenylyl cyclases (ACs) and decreased cyclic adenosine monophosphate (cAMP) levels. In contrast, opioid withdrawal following chronic activation of MOR uncovers AC superactivation and subsequent increases in cAMP and protein kinase A (PKA) activity. Here we investigated (1) whether an increase in cAMP during opioid withdrawal increases the activity of TRPV1 and (2) how opioid withdrawal modulates capsaicin-induced nocifensive behavior in rats. We applied whole-cell patch clamp, microfluorimetry, cAMP assays, radioligand binding, site-directed mutagenesis, and behavioral experiments. Opioid withdrawal significantly increased cAMP levels and capsaicin-induced TRPV1 activity in both transfected human embryonic kidney 293 cells and dissociated dorsal root ganglion (DRG) neurons. Inhibition of AC and PKA, as well as mutations of the PKA phosphorylation sites threonine 144 and serine 774, prevented the enhanced TRPV1 activity. Finally, capsaicin-induced nocifensive behavior was increased during opioid withdrawal in vivo. In summary, our results demonstrate an increased activity of TRPV1 in DRG neurons as a new mechanism contributing to opioid withdrawal-induced hyperalgesia. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
12. Involvement of the peripheral sensory and sympathetic nervous system in the vascular endothelial expression of ICAM-1 and the recruitment of opioid-containing immune cells to inhibit inflammatory pain
- Author
-
Mousa, Shaaban A., Shaqura, Mohammed, Brendl, Ute, Al-Khrasani, Mahmoud, Fürst, Susanna, and Schäfer, Michael
- Subjects
- *
SYMPATHETIC nervous system , *VASCULAR endothelium , *MOLECULES , *CELL adhesion , *CELLULAR immunity , *OPIOIDS , *PAIN perception - Abstract
Abstract: Endogenous opioids are known to be released within certain brain areas following stressful stimuli. Recently, it was shown that also leukocytes are a potential source of endogenously released opioid peptides following stress. They activate sensory neuron opioid receptors and result in the inhibition of local inflammatory pain. An important prerequisite for the recruitment of such leukocytes is the expression of intracellular adhesion molecule-1 (ICAM-1) in blood vessels of inflamed tissue. Here, we investigated the contribution of peripheral sensory and/or sympathetic nerves to the enhanced expression of ICAM-1 simultaneously with the increased recruitment of opioid peptide-containing leukocytes to promote the inhibition of inflammatory pain. Selective degeneration of either peripheral sensory or sympathetic nerve fibers by their respective neurotoxins, capsaicin or 6-hydroxydopamime, significantly reduced the subcutaneous immigration of β-endorphin- (END-) and met-enkephalin- (ENK-)-containing polymorphonuclear leukocytes (PMN) (in the early phase) and mononuclear cells (in the late phase) during painful Freund’s complete adjuvant (FCA) rat hind paw inflammation. In contrast, this treatment did not alter the percentage of opioid peptide-containing leukocytes in the circulation. Calcitonin gene-related peptide- (CGRP-) and tyrosine hydroxylase- (TH-) immunoreactive (IR) nerve fibers were in close contact to ICAM-1 IR blood vessels within inflamed subcutaneous tissue. The selective degeneration of sensory or sympathetic nerve fibers attenuated the enhanced expression of vascular endothelial ICAM-1 after intraplantar (i.pl.) FCA and abolished endogenous opioid peptide-mediated peripheral analgesia. Our results suggest that, during localized inflammatory pain, peripheral sensory and sympathetic nerve fibers augment the expression of vascular endothelial ICAM-1 simultaneously with the increased recruitment of opioid peptide-containing leukocytes which consequently promotes the endogenous opioid peptide-mediated inhibition of inflammatory pain. They support existing evidence about a close link between the nervous and the immune system. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
13. Control of inflammatory pain by chemokine-mediated recruitment of opioid-containing polymorphonuclear cells
- Author
-
Brack, Alexander, Rittner, Heike L., Machelska, Halina, Leder, Kerstin, Mousa, Shaaban A., Schäfer, Michael, and Stein, Christoph
- Subjects
- *
INFLAMMATION , *CHEMOKINES , *OPIOIDS , *HYPERALGESIA - Abstract
Abstract: Opioid-containing leukocytes can counteract inflammatory hyperalgesia. Under stress or after local injection of corticotropin releasing factor (CRF), opioid peptides are released from leukocytes, bind to opioid receptors on peripheral sensory neurons and mediate antinociception. Since polymorphonuclear cells (PMN) are the predominant opioid-containing leukocyte subpopulation in early inflammation, we hypothesized that PMN and their recruitment by chemokines are important for peripheral opioid-mediated antinociception at this stage. Rats were intraplantarly injected with complete Freund''s adjuvant (CFA). Using flow cytometry, immunohistochemistry, and ELISA, leukocyte subpopulations, chemokine receptor (CXCR2) expression on opioid-containing leukocytes and the CXCR2 ligands keratinocyte-derived chemokine (KC), macrophage inflammatory protein-2 (MIP-2) and cytokine-induced neutrophil chemoattractant-2 (CINC-2) were quantified. Paw pressure threshold (PPT) was determined before and after intraplantar and subcutaneous injection of CRF with or without naloxone. PMN depletion was achieved by intravenous injection of an antiserum. Chemokines were blocked by intraplantar injection of anti-MIP-2 and/or anti-KC antiserum. We found that at 2h post CFA (i) intraplantar but not subcutaneous injection of CRF produced dose-dependent and naloxone-reversible antinociception (P<0.05, ANOVA). (ii) Opioid-containing leukocytes in the paw and CRF-induced antinociception were reduced after PMN depletion (P<0.05, t-test). (iii) Opioid-containing leukocytes mostly expressed CXCR2. MIP-2 and KC, but not CINC-2 were detectable in inflamed but not in noninflamed tissue (P<0.05, ANOVA). (iv) Combined but not single blockade of MIP-2 and KC reduced the number of opioid-containing leukocytes and peripheral opioid-mediated antinociception (P<0.05, t-test; P>0.05, ANOVA). In summary, in early inflammation peripheral opioid-mediated antinociception is critically dependent on PMN and their recruitment by CXCR2 chemokines. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
14. Involvement of corticotropin-releasing hormone receptor subtypes 1 and 2 in peripheral opioid-mediated inhibition of inflammatory pain
- Author
-
Mousa, Shaaban A., Bopaiah, C.P., Stein, Christoph, and Schäfer, Michael
- Subjects
- *
INFLAMMATION , *CORTICOTROPIN releasing hormone , *OPIOIDS , *ENDORPHINS - Abstract
In painful inflammation, exogenous as well as endogenous corticotropin-releasing hormone (CRH) can release opioid peptides (mainly β-endorphin) from various types of immune cells and produce antinociception by activating opioid receptors on peripheral sensory nerve endings. CRH mediates its central effects through two high-affinity membrane receptors, the CRH receptor subtypes 1 and 2. It is unclear at present whether the peripheral antinociceptive effects of CRH are mediated through CRH receptor 1 (CRH R1) or CRH receptor 2 (CRH R2). Employing a double-immunocytochemical technique, this study investigated in Wistar rats with Freund''s complete adjuvant-induced hind paw inflammation whether immune cells within blood and inflamed subcutaneous tissue express CRH R1 and/or CRH R2 together with the opioid peptide β-endorphin (END). Additionally, we examined using selective CRH R1 and CRH R2 antagonists whether peripheral CRH-induced antinociception is mediated by the respective CRH receptor subtypes. We found a high degree of co-expression of END together with both CRH R1 and CRH R2 in macrophage/monocytes, granulocytes and lymphocytes within blood and inflamed subcutaneous tissue. Also we observed a high degree of co-localization of CRH R1 and CRH R2 receptors on circulating and resident immune cells. Both the selective CRH R1 antagonist CP-154,526 and the selective CRH R2 antagonist astressin 2B significantly attenuated peripheral antinociceptive effects of CRH indicating the involvement of both CRH receptor subtypes. Taken together, these findings suggest that in inflammatory pain CRH-induced peripheral antinociception is mediated via both CRH R1 and CRH R2 located on END containing immune cells within inflamed sites. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
15. Different mechanisms of intrinsic pain inhibition in early and late inflammation
- Author
-
Machelska, Halina, Schopohl, Julia K., Mousa, Shaaban A., Labuz, Dominika, Schäfer, Michael, and Stein, Christoph
- Subjects
- *
PAIN , *PEPTIDES , *PROTEINS , *OPIOIDS - Abstract
Neuroimmune interactions control pain through activation of opioid receptors on sensory nerves by immune-derived opioid peptides. Here we evaluate mechanisms of intrinsic pain inhibition at different stages of Freund''s adjuvant-induced inflammation of the rat paw. We use immunohistochemistry and paw pressure testing. Our data show that in early (6 h) inflammation leukocyte-derived β-endorphin, met-enkephalin and dynorphin A activate peripheral μ-, δ- and κ-receptors to inhibit nociception. In addition, central opioid mechanisms seem to contribute significantly to this effect. At later stages (4 days), antinociception is exclusively produced by leukocyte-derived β-endorphin acting at peripheral μ and δ receptors. Corticotropin-releasing hormone (CRH) is an endogenous trigger of these effects at both stages. These findings indicate that peripheral opioid mechanisms of pain inhibition gain functional relevance with the chronicity of inflammation. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.